Qiagen, Bayer Partner on Cancer Companion Dx | GenomeWeb

NEW YORK (GenomeWeb News) – Qiagen today said that it will collaborate with Bayer HealthCare on developing companion diagnostics for Bayer drugs with an initial focus on those that target solid tumors.

The companion diagnostic tests will run on Qiagen's QIA symphony automated instruments. In addition, the partners said that they will collaborate on developing technologies for patient profiling, which may result on research-use-only products for exploratory and translational medicine, said Qiagen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.